Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Detection of Maternal Malignancy after Abnormal Noninvasive Prenatal Testing (NIPT)

Mwanasha Hamuza Merrill, Sophie Cahill, Hannah Pepprock, Robert A. Redd, Huma Rana, Katherine Economy, Judy Garber, Ann LaCasce

Blood (2023) 142 (Supplement 1): 7389.

https://doi.org/10.1182/blood-2023-182672

Published: 2023

Journal Articles

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Hodgkin Lymphoma across the United States

Blood (2023) 142 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2023-174589

Published: 2023

Journal Articles

Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy

Jonathan Bakos, Silvia Escribano Serrat, Yazeed Sawalha, Alison Moskowitz, Anna Crawford, Taylor R. Brooks, Brian T. Hill, Ayo S Falade, Reid W. Merryman, Manali Kamdar, Andrew Ip, Gunjan L. Shah, Arash Velayati, McKenzie Sorrell, James A Davis, Irl Brian Greenwell, Ann LaCasce, Brian Hess

Blood (2023) 142 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2023-178740

Published: 2023

Journal Articles

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3084.

https://doi.org/10.1182/blood-2023-189652

Published: 2023

Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2023-173103

Published: 2023

Journal Articles

A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jennifer L Crombie, Austin I Kim, Nancy L. Bartlett, Robert A. Redd, Victoria Patterson, Celeste Carey, Sobana Balasubramanian, Oreofe O. Odejide, Reid W. Merryman, Ann LaCasce, Caron A Jacobson, Eric Jacobsen, Erin M Parry, David C Fisher, Alex F. Herrera, Matthew S Davids, Margaret A. Shipp, Philippe Armand, Geoffrey P. Shouse

Blood (2023) 142 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2023-181067

Published: 2023

Journal Articles

Clinical Outcomes in Patients with High-Dose Methotrexate Toxicity Treated with Vs. without Glucarpidase

Shruti Gupta, Ann LaCasce, Rebecca Karp Leaf, Sarah Kaunfer, David E Leaf

Blood (2023) 142 (Supplement 1): 268.

https://doi.org/10.1182/blood-2023-189432

Published: 2023

Journal Articles

The treatment of Burkitt lymphoma in adults

Jennifer Crombie, Ann LaCasce

Blood (2021) 137 (6): 743–750.

https://doi.org/10.1182/blood.2019004099

Published: 2021

Journal Articles

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

Lakshmi Nayak, Fabio M. Iwamoto, Ann LaCasce, Srinivasan Mukundan, Margaretha G. M. Roemer, Bjoern Chapuy, Philippe Armand, Scott J. Rodig, Margaret A. Shipp

Blood (2017) 129 (23): 3071–3073.

https://doi.org/10.1182/blood-2017-01-764209

Published: 2017

Journal Articles

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann LaCasce, MD, R. Gregory Bociek, MD, Jeffrey Matous, MD, Ahmed Sawas, MD, Paolo Caimi, MD, Stephen M. Ansell, MD PhD, Miguel Islas-Ohlmayer, MD, Eric Cheung, MD, Edward Agura, MD, Caroline Behler, MD, Howland Crosswell, MD, Julie M. Vose, MD MBA, Neil Josephson, MD, Ranjana Advani, MD

Blood (2014) 124 (21): 293.

https://doi.org/10.1182/blood.V124.21.293.293

Published: 2014

Journal Articles

Predictors of Hospice Utilization Among Patients with Lymphoma

Oreofe O. Odejide, MD, Angel M. Cronin, MS, Ann LaCasce, MD, Gregory A. Abel, MD MPH

Blood (2014) 124 (21): 558.

https://doi.org/10.1182/blood.V124.21.558.558

Published: 2014

Journal Articles

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Ian Flinn, Nancy L. Bartlett, MD, Kristie A. Blum, MD, Kirit M Ardeshna, MD FRCPath, Ann LaCasce, MD, Christopher R. Flowers, MD, Andrei R. Shustov, MD, Kenneth Thress, PhD, Fred Zheng, MD PhD, Jeffery Skolnik, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 1725.

https://doi.org/10.1182/blood.V124.21.1725.1725

Published: 2014

Journal Articles

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, MD, Michelle Fanale, MD, Ann LaCasce, MD, Ariela Noy, Paolo Caimi, MD, Samir Parekh, MD, John W Hayslip, MD, Deepa Jagadeesh, MD MPH, Raymond S Lord, Mary J Lechowicz, MD, Rakesh Gaur, MD, Andrea Lucas, RN, Louis M Staudt, MD PhD, Seth M. Steinberg, PhD, Brad Kahl, MD, Jonathan W. Friedberg, MD, Richard F Little, MPH, MD, Nancy L Bartlett, MD, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 395.

https://doi.org/10.1182/blood.V124.21.395.395

Published: 2014

Journal Articles

How I treat Burkitt lymphoma in adults

Caron Jacobson, Ann LaCasce

Blood (2014) 124 (19): 2913–2920.

https://doi.org/10.1182/blood-2014-06-538504

Published: 2014

Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2669.

https://doi.org/10.1182/blood.V120.21.2669.2669

Published: 2012

Journal Articles

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Vicki A. Morrison, MD, Sin-Ho Jung, PhD, Jeffrey Johnson, MS, Ann LaCasce, MD, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD

Blood (2012) 120 (21): 3696.

https://doi.org/10.1182/blood.V120.21.3696.3696

Published: 2012

Journal Articles

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Jeffrey A. Barnes, MD, PhD, Kristen Stevenson, Ephraim P. Hochberg, MD, Tak Takvorian, MD, David C. Fisher, MD, Ann LaCasce, MD, Jennifer R. Brown, MD, PhD, Anuj K. Mahindra, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 3716.

https://doi.org/10.1182/blood.V118.21.3716.3716

Published: 2011

Journal Articles

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Lale Kostakoglu, MD, MPH, Heiko Schoder, MD, Nathan Hall, MD, PhD, David J. Straus, MD, Jeffrey L Johnson, PhD, Lawrence Schwartz, MD, Ann LaCasce, MD, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, George P. Canellos, MD, Bruce D. Cheson, MD

Blood (2011) 118 (21): 3644.

https://doi.org/10.1182/blood.V118.21.3644.3644

Published: 2011

Journal Articles

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Andrew M. Evens, DO, MSc, Ann Vanderplas, M.S., Ann LaCasce, MD, MSc, Allison Crosby, MS, Auayporn Nademanee, M.D., Mark S. Kaminski, MD, Gregory A. Abel, MD, MPH, Michael Millenson, MD, Myron S. Czuczman, MD, Maria A. Rodriguez, MD, Joyce Niland, PhD, Andrew D Zelenetz, MD, PhD, Leo I. Gordon, MD, FACP, Jonathan Friedberg, MD

Blood (2011) 118 (21): 4112.

https://doi.org/10.1182/blood.V118.21.4112.4112

Published: 2011

Journal Articles

Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation

Shira L. Galper, James B. Yu, Peter M. Mauch, Jon F. Strasser, Barbara Silver, Ann LaCasce, Karen J. Marcus, Mary Ann Stevenson, Ming Hui Chen, Andrea K. Ng

Blood (2011) 117 (2): 412–418.

https://doi.org/10.1182/blood-2010-06-291328

Published: 2011

NARROW

Detection of Maternal Malignancy after Abnormal Noninvasive Prenatal Testing (NIPT)

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Hodgkin Lymphoma across the United States

Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Refractory or Relapsed after Frontline R-EPOCH Chemotherapy

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical Outcomes in Patients with High-Dose Methotrexate Toxicity Treated with Vs. without Glucarpidase

The treatment of Burkitt lymphoma in adults

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Predictors of Hospice Utilization Among Patients with Lymphoma

A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

How I treat Burkitt lymphoma in adults

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only